Advertisement

Response to Conventional Therapy and Targeted Molecular Therapy

  • Timothy Craig Allen
  • Anna Sienko
  • Philip T. Cagle
Part of the Molecular Pathology Library book series (MPLB, volume 1)

Abstract

Currently, the standard chemotherapy regimen for non-small cell lung cancer (NSCLC) involves platinum-based anticancer drugs such as cisplatin, which functions by the formation of bulky platinum DNA adducts, along with a third-generation agent such as paclitaxel, gemcitabine, vinorelbine, or irinotecan.1, 2, 3, 4 Nonplatinum agents such as docetaxel, a taxane that functions by disrupting microtubule dynamics via β-tubulin binding, are also frequently used to treat NSCLC patients.4,5 Vinorelbine, a vinca alkaloid, have also been used with some success in treating NSCLC patients.1 The benefits of these standard systemic chemotherapeutic agents is limited for patients with advanced NSCLC, with half of those patients exhibiting an 8- to 11-month median survival despite cisplatinbased therapy.2,6 Along with troubling cisplatin toxicity, the development of cisplatin resistance has become a serious concern.1,3

Keywords

Epidermal Growth Factor Receptor Clin Oncol Epidermal Growth Factor Receptor Mutation KRAS Mutation Epidermal Growth Factor Receptor Inhibitor 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Pujol JL, Barlesi F, Daures JP. Should chemotherapy combinations for advanced non-small cell lung cancer be platinum-based? A meta-analysis of phase III randomized trials. Lung Cancer 2006;51:335–345.CrossRefPubMedGoogle Scholar
  2. 2.
    Rosell R, Cobo M, Isla D, et al. Applications of genomics in NSCLC. Lung Cancer 2005;2:S33–S40.CrossRefGoogle Scholar
  3. 3.
    Wang G, Reed E, Li QQ. Molecular basis of cellular responses to cisplatin chemotherapy in non-small cell lung cancer. Oncol Rep 2004;12:955–965.PubMedGoogle Scholar
  4. 4.
    Silvestri GA, Rivera MP. Targeted therapy for the treatment of advanced non-small cell lung cancer. A review of the epidermal growth factor receptor antagonists. Chest 2005;128:3975–3984.CrossRefPubMedGoogle Scholar
  5. 5.
    Fanucchi M, Khuri FR. Taxanes in the treatment of nonsmall cell lung cancer. Treat Respir Med 2006;5:181–191.CrossRefPubMedGoogle Scholar
  6. 6.
    Belani CP. Optimizing chemotherapy for advanced nonsmall cell lung cancer: focus on docetaxel. Lung Cancer 2005;50:S3–S8.CrossRefPubMedGoogle Scholar
  7. 7.
    Rosell R, Fossella F, Milas L. Molecular markers and targeted therapy with novel agents: prospects in the treatment of non-small cell lung cancer. Lung Cancer 2002;38:S43–S49.CrossRefGoogle Scholar
  8. 8.
    Rosell R, Cecere F, Santarpia M, et al. Predicting the outcome of chemotherapy for lung cancer. Curr Opin Pharmacol 2006;6:1–9.CrossRefGoogle Scholar
  9. 9.
    Santarpia M, Altavilla G, Salazar F, et al. From the bench to the bed: individualizing treatment in non-small-cell lung cancer. Clin Transl Oncol 2006;8:71–76.CrossRefPubMedGoogle Scholar
  10. 10.
    Taron M, Rosell R, Felip E, et al. BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer. Hum Mol Genet 2004;13:2443–2449.CrossRefPubMedGoogle Scholar
  11. 11.
    Csiki I, Yanagisawa K, Haruki N, et al. Thioredoxin-1 modulates transcription of cyclooxygenase-2 via hypoxiainducible factor-1α in non-small cell lung cancer, Cancer Res 2006;66:143–150.CrossRefPubMedGoogle Scholar
  12. 12.
    Seve P, Dumontet C. Chemoresistance in non-small cell lung cancer. Curr Med Chem Anticancer Agents 2005;5:73–88.CrossRefPubMedGoogle Scholar
  13. 13.
    Garcia-Campelo R, Alonso-Curbera G, Anton Aparicio LM, Rosell R. Pharmacogenomics in lung cancer: an analysis of DNA repair gene expression in patients treated with platinum-based chemotherapy. Expert Opin Pharmacother 2005;6:2015–2026.CrossRefPubMedGoogle Scholar
  14. 14.
    Simon GR, Sharma S, Cantor A, et al. Polymorphisms in ERCC1 and grade 3 or 4 toxicity in non-small cell lung cancer patients. Clin Cancer Res 2005;11:1534–1538.CrossRefGoogle Scholar
  15. 15.
    Wachters FM, Wong LS, Timens W, et al. ERCC1, hRad51, and BRCA1 protein expression in relation to tumour response and survival of stage III/IV NSCLC patients treated with chemotherapy. Lung Cancer 2005;50:211–219.CrossRefPubMedGoogle Scholar
  16. 16.
    Ramirez JL, Rosell R, Taron M, et al. 14-3-3s methylation in pretreatment serum circulating DNA of cisplatin-plusgemcitabine-treated advanced non-small-cell lung cancer patients predicts survival: the Spanish lung cancer group. J Clin Oncol 2005;23:9105–9112.CrossRefPubMedGoogle Scholar
  17. 17.
    Chan TA, Hermeking H, Lengauer C, et al. 14-3-3σ is required to prevent mitotic catastrophe after DNA damage. Nature 1999;401:616–620.CrossRefPubMedGoogle Scholar
  18. 18.
    Osada H, Tatematsu Y, Yatabe Y, et al. Frequent and histological type-specific inactivation of 14-3-3σ in human lung cancers. Oncogene 2002;21:2418–2424.CrossRefPubMedGoogle Scholar
  19. 19.
    de las Penas R, Sanchez-Ronco M, Alberola V, et al. Polymorphisms in DNA repair genes modulate survival in cisplatin/gemcitabine-treated non-small-cell lung cancer patients. Ann Oncol 2006;17:668–675.CrossRefPubMedGoogle Scholar
  20. 20.
    Massarelli E, Herbst RS. Use of novel second-line targeted therapies in non-small cell lung cancer. Semin Oncol 2006;33:S9–S16.CrossRefPubMedGoogle Scholar
  21. 21.
    Ramalingam S, Belani CP. Molecularly-targeted therapies for non-small cell lung cancer. Expert Opin Pharmacother 2005;6:2667–2679.CrossRefPubMedGoogle Scholar
  22. 22.
    Lee SM. Is EGFR expression important in non-small cell lung cancer? Thorax 2006;66:98–99.CrossRefGoogle Scholar
  23. 23.
    Hirsch FR, Lippman SM. Advances in the biology of lung cancer chemoprevention. J Clin Oncol 2005;23:3186–3197.CrossRefPubMedGoogle Scholar
  24. 24.
    Rusch V, Klimstra D, Venkatraman E, et al. Overexpression of the epidermal growth factor receptor and its ligand transforming growth factor alpha is frequent in resectable non-small cell lung cancer but does not predict tumor progression. Clin Cancer Res 1997;3:515–522.PubMedGoogle Scholar
  25. 25.
    Fontanini G, Vignati S, Boldrini L, et al. Vascular endothelial growth factor is associated with neovascularization and influences progression of non-small cell lung carcinoma. Clin Cancer Res 1997;3:861–865.PubMedGoogle Scholar
  26. 26.
    Cappuzzo F, Varella-Garcia M, Shigematsu H, el al. Increased HER 2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patients, J Clin Oncol 2005;23:5007–5018.CrossRefPubMedGoogle Scholar
  27. 27.
    Shigematsu H, Lin L, Takahashi T, et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 2005;97:339–346.PubMedGoogle Scholar
  28. 28.
    Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 2004;101:13306–13311.CrossRefPubMedGoogle Scholar
  29. 29.
    Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304:1497–1500.CrossRefPubMedGoogle Scholar
  30. 30.
    Sridhar SS, Seymour L, Shepherd FA. Inhibitors of epidermal-growth-factor receptors: a review of clinical research with a focus on non-small-cell cancer. Lancet Oncol 2003;4:397–406.CrossRefPubMedGoogle Scholar
  31. 31.
    Raben D, Helfrich B, Chan DC, et al. The effects of cetuximab alone and in combination with radiation and/or chemotherapy in lung cancer. Clin Cancer Res 2005;11:795–805.PubMedGoogle Scholar
  32. 32.
    Ciardiello F, De Vita F, Orditura M, et al. Epidermal growth factor receptor tyrosine kinase inhibitors in late stage clinical trials. Expert Opin Emerg Drugs 2003;8:501–514.CrossRefPubMedGoogle Scholar
  33. 33.
    Ji H, Li D, Chen L, et al. The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies. Cancer Cell 2006;9:485–495.CrossRefPubMedGoogle Scholar
  34. 34.
    Humblet Y. Cetuximab: an IgG(1) monoclonal antibody for the treatment of epidermal growth factor receptor-expressing tumours. Expert Opin Pharmacother 2004;5:1621–1633.CrossRefPubMedGoogle Scholar
  35. 35.
    Harding J, Burtness B. Cetuximab: an epidermal growth factor receptor chimeric human-murine monoclonal antibody. Drugs Today (Barc) 2005;41:107–127.CrossRefGoogle Scholar
  36. 36.
    Herbst RS, Langer CJ. Epidermal growth factor receptors as a target for cancer treatment: the emerging role of IMCC225 in the treatment of lung and head and neck cancers. Semin Oncol 2002;29:S27–S36.CrossRefGoogle Scholar
  37. 37.
    Kim ES, Vokes EE, Kies MS. Cetuximab in cancers of the lung and head and neck. Semin Oncol 2004;31:S61–S67.CrossRefGoogle Scholar
  38. 38.
    Khalil MY, Grandis JR, Shin DM. Targeting epidermal growth factor receptor: novel therapeutics in the management of cancer. Expert Rev Anticancer Ther 2003;3:367–380.CrossRefPubMedGoogle Scholar
  39. 39.
    Buter J, Giaccone G. EGFR inhibitors in lung cancer. Oncology (Williston Park) 2005;19:1667–1668.Google Scholar
  40. 40.
    Govindan R. Cetuximab in advanced non-small cell lung cancer. Clin Cancer Res 2004;10:S4241–S4244.CrossRefGoogle Scholar
  41. 41.
    Thienelt CD, Bunn PA, Hanna N, et al. Multicenter phase I/II study of cetuximab with paclitaxel and carboplatin in untreated patients with stage IV non-small-cell lung cancer. J Clin Oncol 2005;23:8786–8793.CrossRefPubMedGoogle Scholar
  42. 42.
    Robert F, Blumenschein G, Herbst RS, et al. Phase I/IIa study of cetuximab with gemcitabine plus carboplatin in patients with chemotherapy-naive advanced non-small-cell lung cancer. J Clin Oncol 2005;23:9089–9096.CrossRefPubMedGoogle Scholar
  43. 43.
    Vokes EE, Chu E. Anti-EGFR therapies: clinical experience in colorectal, lung, and head and neck cancers. Oncology (Williston Park) 2006;20:S15–S25.Google Scholar
  44. 44.
    Giaccone G, Rodriguez JA. EGFR inhibitors: what have we learned from the treatment of lung cancer? Nat Clin Pract Oncol 2005;2:554–561.CrossRefPubMedGoogle Scholar
  45. 45.
    Govindan R, Natale R, Wade J, et al. Efficacy and safety of gefitinib in chemonaive patients with advanced non-small cell lung cancer treated in an Expanded Access Program. Lung Cancer 2006;[Epub ahead of print]Google Scholar
  46. 46.
    Miller VA, Kris MG, Shah N, et al. Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer. J Clin Oncol 2004;22:1103–1109.CrossRefPubMedGoogle Scholar
  47. 47.
    Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 2003;290:2149–2158.CrossRefPubMedGoogle Scholar
  48. 48.
    Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial). J Clin Oncol 2003;21:2237–2246.CrossRefPubMedGoogle Scholar
  49. 49.
    Amann J, Kalyankrishna S, Massion PP, et al. Aberrant epidermal growth factor receptor signaling and enhanced sensitivity to EGFR inhibitors in lung cancer. Cancer Res 2005;65:226–235.PubMedGoogle Scholar
  50. 50.
    Han SW, Kim TY, Hwang PG, et al. Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib. J Clin Oncol 2005;23:2493–2501.CrossRefPubMedGoogle Scholar
  51. 51.
    Maione P, Gridelli C, Troiani T, Ciardiello F. Combining targeted therapies and drugs with multiple targets in the treatment of NSCLC. Oncologist 2006;11:274–284.CrossRefPubMedGoogle Scholar
  52. 52.
    Giaccone G, Herbst RS, Manegold C, et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial—INTACT 1. J Clin Oncol 2004;22:777–784.CrossRefPubMedGoogle Scholar
  53. 53.
    Herbst RS, Giaccone G, Schiller JH, et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial—INTACT 2. J Clin Oncol 2004;22:785–994.CrossRefPubMedGoogle Scholar
  54. 54.
    Thatcher N, Chang A, Parikh P, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomized, placebo-controlled, muticentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 2005;366:1527–1537.CrossRefPubMedGoogle Scholar
  55. 55.
    Lynch T, Kim E. Optimizing chemotherapy and targeted agent combinations in NSCLC. Lung Cancer 2005;50:S25–S32.CrossRefPubMedGoogle Scholar
  56. 56.
    Shepherd FA, Rodriguez Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353:123–132.CrossRefPubMedGoogle Scholar
  57. 57.
    Pao W, Wang TY, Riely GJ, et al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med 2005;2:e17.CrossRefPubMedGoogle Scholar
  58. 58.
    Yano S, Matsumori Y, Ikuta K, et al. Current status and perspective of angiogenesis and antivascular therapeutic strategy: non-small cell lung cancer. Int J Clin Oncol 2006;11:73–81.CrossRefPubMedGoogle Scholar
  59. 59.
    Lyseng-Williamson KA, Robinson DM. Spotlight on bevacizumab in advanced colorectal cancer, breast cancer, and non-small cell lung cancer. BioDrugs 2006;20:193–195.CrossRefPubMedGoogle Scholar
  60. 60.
    Midgley R, Kerr D. Bevacizumab—current status and future directions. Ann Oncol 2005;16:999–1004.CrossRefPubMedGoogle Scholar
  61. 61.
    Johnson DH, Fehrenbacher L, Novotny WF, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic nonsmall-cell lung cancer. J Clin Oncol 2004;22:2184–2191.CrossRefPubMedGoogle Scholar
  62. 62.
    Sandler AB, Johnson DH, Herbst RS. Anti-vascular endothelial growth factor monoclonals in non-small cell lung cancer. Clin Cancer Res 2004;10:S4258–S4262.CrossRefGoogle Scholar
  63. 63.
    Belvedere O, Grossi F. Lung cancer highlights from ASCO 2005. Oncologist 2006;11:39–50.CrossRefPubMedGoogle Scholar
  64. 64.
    de Castro G, Puglisi F, de Azambuja E, et al. Angiogenesis and cancer: a cross-talk between basic science and clinical trials (the “do ut des” paradigm). Crit Rev Oncol Hematol 2006;59:40–50.CrossRefGoogle Scholar
  65. 65.
    Herbst RS, Johnson DH, Mininberg E, et al. A. Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer. J Clin Oncol 2005;23:2544–2555.CrossRefPubMedGoogle Scholar
  66. 66.
    Morgensztern D, Govindan R. Clinical trials of antiangiogenic therapy in non-small cell lung cancer: focus on bevacizumab and ZD6474. Expert Rev Anticancer Ther 2006;6:545–551.CrossRefPubMedGoogle Scholar
  67. 67.
    Lee D, Heymach JV. Emerging antiangiogenic agents in lung cancer. Clin Lung Cancer 2006;7:304–308.CrossRefPubMedGoogle Scholar
  68. 68.
    Wakelee HA, Schiller JH. Targeting angiogenesis with vascular endothelial growth factor receptor small-molecule inhibitors: novel agents with potential in lung cancer. Clin Lung Cancer 2005;7:S31–S38.CrossRefPubMedGoogle Scholar
  69. 69.
    Cascone T, Troiani T, Morelli MP, et al. Antiangiogenic drugs in non-small cell lung cancer treatment. Curr Opin Oncol 2006;18:151–155.CrossRefPubMedGoogle Scholar
  70. 70.
    Krawczyk P, Chocholska S, Milanowski J. Anti-HER therapeutic agents in the treatment of non-small-cell lung cancer. Ann Univ Mariae Curie Sklodowska [Med] 2003;8:113–117.Google Scholar
  71. 71.
    Heinmoller P, Gross C, Beyser K, et al. HER2 status in nonsmall cell lung cancer: results from patient screening for enrollment to a phase II study of herceptin. Clin Cancer Res 2003;9:5238–5243.PubMedGoogle Scholar
  72. 72.
    Lara PN Jr, Laptalo L, Longmate J, et al. Trastuzumab plus docetaxel in HER2/neu-positive non-small-cell lung cancer: a California Cancer Consortium screening and phase II trial. Clin Lung Cancer 2004;5:231–236.CrossRefPubMedGoogle Scholar
  73. 73.
    Hirsch FR, Langer CJ. The role of HER2/neu expression and trastuzumab in non-small cell lung cancer. Semin Oncol 2004;31:S75–S82.CrossRefGoogle Scholar
  74. 74.
    Clamon G, Herndon J, Kern J, et al. Lack of trastuzumab activity in nonsmall cell lung carcinoma with overexpression of erb-B2: 39810: a phase II trial of Cancer and Leukemia Group B. Cancer 2005;103:1670–1675.CrossRefPubMedGoogle Scholar
  75. 75.
    Gatzemeier U, Groth G, Butts C, et al. Randomized phase II trial of gemcitabine-cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer. Ann Oncol 2004;15:19–27.CrossRefPubMedGoogle Scholar
  76. 76.
    Friess T, Scheuer W, Hasmann M. Combination treatment with erlotinib and pertuzumab against human tumor xenografts is superior to monotherapy. Clin Cancer Res 2005;11:5300–5309.CrossRefPubMedGoogle Scholar
  77. 77.
    Franklin MC, Carey KD, Vajdos FF, et al. Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. Cancer Cell 2004;5:317–328.CrossRefPubMedGoogle Scholar
  78. 78.
    Bianco AR. Targeting c-erbB2 and other receptors of the c-erbB family: rationale and clinical applications. J Chemother 2004;16:52–54.PubMedGoogle Scholar
  79. 79.
    Han JY, Oh SH, Morgillo F, et al. Hypoxia-inducible factor 1alpha and antiangiogenic activity of farnesyltransferase inhibitor SCH66336 in human aerodigestive tract cancer. J Natl Cancer Inst 2005;97:1272–1286.PubMedCrossRefGoogle Scholar
  80. 80.
    Dragnev KH, Petty WJ, Ma Y, et al. Nonclassical retinoids and lung carcinogenesis. Clin Lung Cancer 2005;6:237–244.CrossRefPubMedGoogle Scholar
  81. 81.
    Brabender J, Metzger R, Salonga D, et al. Comprehensive expression analysis of retinoic acid receptors and retinoid X receptors in non-small cell lung cancer: implications for tumor development and prognosis. Carcinogenesis 2005;26:525–530.CrossRefPubMedGoogle Scholar
  82. 82.
    Rigas JR, Dragnev KH. Emerging role of rexinoids in non-small cell lung cancer: focus on bexarotene. Oncologist 2005;10:22–33.CrossRefPubMedGoogle Scholar
  83. 83.
    Nandan, R. Promising results achieved with a combination of chemotherapy and two retinoids in patients with advanced non-small-cell lung cancer. Lung Cancer 2006;51:387–388.CrossRefPubMedGoogle Scholar
  84. 84.
    Digel W, Lubbert M. DNA methylation disturbances as novel therapeutic target in lung cancer: preclinical and clinical results. Crit Rev Oncol Hematol 2005;55:1–11.CrossRefPubMedGoogle Scholar
  85. 85.
    Wang WL, Healy ME, Sattler M, et al. Growth inhibition and modulation of kinase pathways of small cell lung cancer cell lines by the novel tyrosine kinase inhibitor STI 571. Oncogene 2000;19:3521–3528.CrossRefPubMedGoogle Scholar
  86. 86.
    Johnson FM, Krug LM, Tran HT, et al. Phase I studies of imatinib mesylate combined with cisplatin and irinotecan in patients with small cell lung carcinoma. Cancer 2000;106:366–374.CrossRefGoogle Scholar
  87. 87.
    Dy GK, Miller AA, Mandrekar SJ, et al. A phase II trial of imatinib (ST1571) in patients with c-kit expressing relapsed small-cell lung cancer: a CALGB and NCCTG study. Ann Oncol 2005;16:1811–1816.CrossRefPubMedGoogle Scholar
  88. 88.
    Yokoyama T, Miyazawa K, Yoshida T, Ohyashiki K. Combination of vitamin K2 plus imatinib mesylate enhances induction of apoptosis in small cell lung cancer cell lines. Int J Oncol 2005;26:33–40.PubMedGoogle Scholar
  89. 89.
    Maulik G, Bharti A, Khan E, et al. Modulation of c-Kit/SCF pathway leads to alterations in topoisomerase-I activity in small cell clung cancer. J Environ Pathol Toxicol Oncol 2004;23:237–251.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC. 2008

Authors and Affiliations

  • Timothy Craig Allen
    • 1
  • Anna Sienko
    • 2
  • Philip T. Cagle
    • 3
    • 4
  1. 1.Department of PathologyUniversity of Texas Health Center at TylerTylerUSA
  2. 2.Department of PathologyMethodist HospitalHoustonUSA
  3. 3.Pathology and Laboratory MedicineWeill Medical College of Cornell UniversityNew York
  4. 4.The Methodist HospitalHoustonUSA

Personalised recommendations